A MULTICENTER, OPEN-LABEL, MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF UCB7665 IN SUBJECTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA
Phase of Trial: Phase II
Latest Information Update: 04 Oct 2017
At a glance
- Drugs UCB 7665 (Primary)
- Indications Immune thrombocytopenic purpura
- Focus Adverse reactions
- Sponsors UCB
- 17 Aug 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.
- 17 Aug 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
- 25 Apr 2016 According to an UCB media release, first results from this trial are expected in the second half of 2017.